Pharmaceutical Technology Quotes

Where there were once several competing approaches to medicine, there is now only one that matters to most hospitals, insurers, and the vast majority of the public. One that has been shaped to a great degree by the successful development of potent cures that followed the discovery of sulfa drugs. Aspiring caregivers today are chosen as much (or more) for their scientific abilities, their talent for mastering these manifold technological and pharmaceutical advances as for their interpersonal skills. A century ago most physicians were careful, conservative observers who provided comfort to patients and their families. Today they act: They prescribe, they treat, they cure. They routinely perform what were once considered miracles. The result, in the view of some, has been a shift in the profession from caregiver to technician. The powerful new drugs changed how care was given as well as who gave it.

The problem is that doctors today often assume that something mysterious and unidentified has gone wrong with labor or that the woman's body is somehow "inadequate" - what I call the "woman's body as a lemon" assumption. For a variety of reasons, a lot of women have also come to believe that nature made a serious mistake with their bodies. This belief has become so strong in many that they give in to pharmaceutical or surgical treatments when patience and recognition of the normality and harmlessness of the situation would make for better health for them and their babies and less surgery and technological intervention in birth. Most women need encouragement and companionship more than they need drugs.

Why aren’t average Americans more upset about the fact that they are paying the pharmaceutical freight for the rest of the world—including a number of countries that have significantly higher per capita incomes than the United States?

Until fairly recently, every family had a cornucopia of favorite home remedies--plants and household items that could be prepared to treat minor medical emergencies, or to prevent a common ailment becoming something much more serious. Most households had someone with a little understanding of home cures, and when knowledge fell short, or more serious illness took hold, the family physician or village healer would be called in for a consultation, and a treatment would be agreed upon. In those days we took personal responsibility for our health--we took steps to prevent illness and were more aware of our bodies and of changes in them. And when illness struck, we frequently had the personal means to remedy it. More often than not, the treatment could be found in the garden or the larder. In the middle of the twentieth century we began to change our outlook. The advent of modern medicine, together with its many miracles, also led to a much greater dependency on our physicians and to an increasingly stretched healthcare system. The growth of the pharmaceutical industry has meant that there are indeed "cures" for most symptoms, and we have become accustomed to putting our health in the hands of someone else, and to purchasing products that make us feel good. Somewhere along the line we began to believe that technology was in some way superior to what was natural, and so we willingly gave up control of even minor health problems.

There are lots of planned economies-the United States is a planned economy, for example. I mean, we talk ourselves as a "free market", but that's baloney. The only parts of the U.S. economy that are internationally competitive are the planned parts, the state-subsidized parts--like capital-intensive agriculture (which has a state-guaranteed market as a cushion in case there are excesses); or high-technology industry (which is dependent on the Pentagon system); or pharmaceuticals (which is massively subsidized by publically funded research). Those are the parts of the U.S. economy that are functioning well.

In newspapers, magazines and on television, the public has been warned off the very vitamins and other supplements that have been repeatedly proven to reduce illness in practically every instance. The effective use of food supplements and natural diet saves money, pain and lives... and you have been told not to do it. If you want something done right you have to do it yourself. This especially includes your healthcare. One of the most common questions about vitamin therapy is, are huge doses safe? This book will help answer that question once and for all, and while we are at it, here’s the answer in advance. Yes. Megadoses of vitamins are very safe. Vitamins do not cause even one death per year. Pharmaceutical drugs, taken as directed, cause over 100 000 deaths annually. Still it is granted that we need access to all the tools that medicine and technology can provide, when used with caution. We must also fully use our natural resources of therapeutic nutrition and vitamins. To limit ourselves to pharmaceutical medicine is like going into the ring to fight the champ with one hand tied behind our backs.

We fine-tune our moods with pharmaceuticals and classic rock. Craft our meals around our allergies and ideologies. Customize our bodies with cross training, with ink and metal, with surgery and wearable technologies. We can choose a vehicle to express our hipness or hostility. We can move to a neighborhood that matches our social values, find a news outlet that mirrors our politics, create a social network that “likes” everything we say or post. With each transaction and upgrade, each choice and click, life moves closer to us, and the world becomes our world.

All the recent marketing successes have been PR successes, not advertising successes. To name a few: Starbucks, The Body Shop, Amazon.com, Yahoo!, eBay, Palm, Google, Linus, PlayStation, Harry Potter, Botox, Red Bull, Microsoft, Intel, and BlackBerry. A closer look at the history of most major brands shows this to be true. As a matter of fact, an astonishing number of well-known brands have been built with virtually no advertising at all. Anita Roddick built The Body Shop into a worldwide brand without any advertising. Instead she traveled the world looking for ingredients for her natural cosmetics, a quest that resulted in endless publicity. Until recently Starbucks didn’t spend a hill of beans on advertising either. In its first ten years, the company spent less that $10 million (total) on advertising in the United States, a trivial amount for a brand that delivers annual sales of $1.3 billion today. Wal-Mart became the world’s largest retailer, ringing up sales approaching $200 billion, with little advertising. Sam’s Club, a Wal-Mart sibling, averages $56 million per store with almost no advertising. In the pharmaceutical field, Viagra, Prozac, and Vioxx became worldwide brands with almost no advertising. In the toy field, Beanie Babies, Tickle Me Elmo, and Pokémon became highly successful brands with almost no advertising. In the high-technology field, Oracle, Cisco, and SAP became multibillion-dollar companies (and multibillion-dollar brands) with almost no advertising.

If you were going to start a bioengineering company, Henry, what would you do? Would you make products to help mankind, to fight illness and disease? Dear me, no. That’s a terrible idea. A very poor use of new technology.” Hammond shook his head sadly. “Yet, you’ll remember,” he said, “the original genetic engineering companies, like Genentech and Cetus, were all started to make pharmaceuticals. New drugs for mankind. Noble, noble purpose. Unfortunately, drugs face all kinds of barriers. FDA testing alone takes five to eight years—if you’re lucky. Even worse, there are forces at work in the marketplace. Suppose you make a miracle drug for cancer or heart disease—as Genentech did. Suppose you now want to charge a thousand dollars or two thousand dollars a dose. You might imagine that is your privilege. After all, you invented the drug, you paid to develop and test it; you should be able to charge whatever you wish. But do you really think that the government will let you do that? No, Henry, they will not. Sick people aren’t going to pay a thousand dollars a dose for needed medication—they won’t be grateful, they’ll be outraged. Blue Cross isn’t going to pay it. They’ll scream highway robbery. So something will happen. Your patent application will be denied. Your permits will be delayed. Something will force you to see reason—and to sell your drug at a lower cost. From a business standpoint, that makes helping mankind a very risky business. Personally, I would never help mankind.

free to pursue new options even if such options imply loss of profits for selected industries. The same is clearly true in pharmaceutical research, in the pursuit of alternatives to the internal-combustion engine, and in many other technological frontiers. I do not think that the development of new technologies should be placed in the control of old technologies; the temptation to suppress the competition is too great. If we Americans live in a free-enterprise society, let us see substantial independent enterprise in all of the technologies upon which our future may depend. If organizations devoted to technological innovation and its boundaries of acceptability are not challenging (and perhaps even offending) at least some powerful groups, they are not accomplishing their purpose.

Dr. Fauci’s business closures pulverized America’s middle class and engineered the largest upward transfer of wealth in human history. In 2020, workers lost $3.7 trillion while billionaires gained $3.9 trillion.46 Some 493 individuals became new billionaires,47 and an additional 8 million Americans dropped below the poverty line.48 The biggest winners were the robber barons—the very companies that were cheerleading Dr. Fauci’s lockdown and censoring his critics: Big Technology, Big Data, Big Telecom, Big Finance, Big Media behemoths (Michael Bloomberg, Rupert Murdoch, Viacom, and Disney), and Silicon Valley Internet titans like Jeff Bezos, Bill Gates, Mark Zuckerberg, Eric Schmidt, Sergey Brin, Larry Page, Larry Ellison, and Jack Dorsey. The very Internet companies that snookered us all with the promise of democratizing communications made it impermissible for Americans to criticize their government or question the safety of pharmaceutical products; these companies propped up all official pronouncements while scrubbing all dissent. The same Tech/Data and Telecom robber barons, gorging themselves on the corpses of our obliterated middle class, rapidly transformed America’s once-proud democracy into a censorship and surveillance police state from which they profit at every turn.

If you were going to start a bioengineering company, Henry, what would you do? Would you make products to help mankind, to fight illness and disease? Dear me, no. That’s a terrible idea. A very poor use of new technology.” Hammond shook his head sadly. “Yet, you’ll remember,” he said, “the original genetic engineering companies, like Genentech and Cetus, were all started to make pharmaceuticals. New drugs for mankind. Noble, noble purpose. Unfortunately, drugs face all kinds of barriers. FDA testing alone takes five to eight years—if you’re lucky. Even worse, there are forces at work in the marketplace. Suppose you make a miracle drug for cancer or heart disease—as Genentech did. Suppose you now want to charge a thousand dollars or two thousand dollars a dose. You might imagine that is your privilege. After all, you invented the drug, you paid to develop and test it; you should be able to charge whatever you wish. But do you really think that the government will let you do that? No, Henry, they will not. Sick people aren’t going to pay a thousand dollars a dose for needed medication—they won’t be grateful, they’ll be outraged. Blue Cross isn’t going to pay it. They’ll scream highway robbery. So something will happen. Your patent application will be denied. Your permits will be delayed. Something will force you to see reason—and to sell your drug at a lower cost. From a business standpoint, that makes helping mankind a very risky business. Personally, I would never help mankind

Tim Tigner began his career in Soviet Counterintelligence with the US Army Special Forces, the Green Berets. That was back in the Cold War days when, “We learned Russian so you didn't have to,” something he did at the Presidio of Monterey alongside Recon Marines and Navy SEALs. With the fall of the Berlin Wall, Tim switched from espionage to arbitrage. Armed with a Wharton MBA rather than a Colt M16, he moved to Moscow in the midst of Perestroika. There, he led prominent multinational medical companies, worked with cosmonauts on the MIR Space Station (from Earth, alas), chaired the Association of International Pharmaceutical Manufacturers, and helped write Russia’s first law on healthcare. Moving to Brussels during the formation of the EU, Tim ran Europe, Middle East, and Africa for a Johnson & Johnson company and traveled like a character in a Robert Ludlum novel. He eventually landed in Silicon Valley, where he launched new medical technologies as a startup CEO. In his free time, Tim has climbed the peaks of Mount Olympus, hang glided from the cliffs of Rio de Janeiro, and ballooned over Belgium. He earned scuba certification in Turkey, learned to ski in Slovenia, and ran the Serengeti with a Maasai warrior. He acted on stage in Portugal, taught negotiations in Germany, and chaired a healthcare conference in Holland. Tim studied psychology in France, radiology in England, and philosophy in Greece. He has enjoyed ballet at the Bolshoi, the opera on Lake Como, and the symphony in Vienna. He’s been a marathoner, paratrooper, triathlete, and yogi.  Intent on combining his creativity with his experience, Tim began writing thrillers in 1996 from an apartment overlooking Moscow’s Gorky Park. Decades later, his passion for creative writing continues to grow every day. His home office now overlooks a vineyard in Northern California, where he lives with his wife Elena and their two daughters. Tim grew up in the Midwest, and graduated from Hanover College with a BA in Philosophy and Mathematics. After military service and work as a financial analyst and foreign-exchange trader, he earned an MBA in Finance and an MA in International Studies from the University of Pennsylvania’s Wharton and Lauder Schools.  Thank you for taking the time to read about the author. Tim is most grateful for his loyal fans, and loves to correspond with readers like you. You are welcome to reach him directly at tim@timtigner.com.

The Western medical model — and I don't mean the science of it, I mean the practice of it, because the science is completely at odds with the practice — makes two devastating separations. First of all we separate the mind from the body, we separate the emotions from the physiology. So we don't see how the physiology of people reflects their lifelong emotional experience. So we separate the mind from the body, which is not something that traditional medicine has done, I mean, Ayuverdic or Chinese medicine or shamanic tribal cultures and medicinal practices throughout the world have always recognized that mind and body are inseparable. They intuitively knew it. Many Western practitioners have known this and even taught it, but in practice we ignore it. And then we separate the individual from the environment. The studies are clear, for example, that when people are emotionally isolated they tend to get sick more quickly and they succumb more rapidly to their disease. Why? Because people's physiology is completely related to their psychological, social environment and when people are isolated and alone their stress levels are much higher because there's nothing there to help them moderate their stress. And physiologically it is straightforward, you know, it takes a five-year-old kid to understand it. However because in practice we separate them... when somebody shows up with an inflamed joint, all we do is we give them an anti-inflammatory or because the immune system is hyperactive and is attacking them we give them a medication to suppress their immune system or we give them a stress hormone like cortisol or one of its analogues, to suppress the inflammation. But we never ask: "What does this manifest about your life?", "What does this say about your relationships?", "How stressful is your job?", "To what extent do you lack control in your life?", "Where are you not authentic?", "How are you trying to work so hard to meet your attachment needs by suppressing yourself?" (because that is what you learn to do as a kid). Then we do all this research that has to do with cell biology, so we keep looking for the cause of cancer in the cell. Now there's a wonderful quote in the New York Times a couple of years ago they did a series on cancer and somebody said: "Looking for the cause of cancer inside the individual cell is like trying to understand a traffic jam by studying the internal combustion engine." We will never understand it, but we spend hundreds of billions of dollars a year looking for the cause of cancer inside the cell, not recognizing that the cell exists in interaction with the environment and that the genes are modulated by the environment, they are turned on and off by the environment. So the impact of not understanding the unity of emotions and physiology on one hand and in the other hand the relationship between the individual and the environment.. in other words.. having a strictly biological model as opposed to what has been called a bio-psycho-social, that recognizes that the biology is important, but it also reflects our psychological and social relationships. And therefore trying to understand the biology in isolation from the psychological and social environment is futile. The result is that we are treating people purely through pharmaceuticals or physical interventions, greatly to the profit of companies that manufacture pharmaceuticals and which fund the research, but it leaves us very much in the dark about a) the causes and b) the treatment, the holistic treatment of most conditions. So that for all our amazing interventions and technological marvels, we are still far short of doing what we could do, were we more mindful of that unity. So the consequences are devastating economically, they are devastating emotionally, they are devastating medically.

WaterLess Urinal Swachh Bharat Abhiyan (Clean India Mission) accelerate sanitation coverage in rural and urban areas. Stakeholders and people from all sections of society have welcomed it as a major step to achieve a healthy and hygienic environment for the citizens of India. This is retrofit waterless urinal technology that gets fitted at base of urinal bowl. It consists of an inlet and outlet cartridge through which urine passes and seals the outlet once the urine is drained out. The technology converts conventional urinal into waterless urinal. No need to remove the old urinal bowl. Advantages:- Waterless urinals do not require a constant source of water Can be built and repaired with locally available materials Low capital and operating costs Waterless urinals produce fewer odours than urinals with water flush and also have no problems with urinal cakes (odour and urinal cakes occur when urine is mixed with water) Waterless urinals contribute to water saving at the greatest possible degree Waterless urinals allow the pure and undiluted collection of urine for reuse, e.g. as fertilizer in urban farming (after appropriate treatment, e.g. storage) and can contribute to closed loop economy, or for effective anaerobic treatment by e.g. an anaerobic ammonium oxidation (anamox) reactor Surface water and aquifers are protected from nutrients and pharmaceuticals if the urine is collected separately Special Feature :- One time fitment Hygienic - Dry restroom prevents bacteria cultivation No Flushing Allocation of transport resources, including the management and regulation of existing transportation activities. No Consumables Waterless and Odorless No Recurring Costs Longer Shelf Life Low & Easy Maintenance Just wipe and clean Structural Feature :- Thin-walled lighted weight Low porosity Ease of transportation Modular Design Flexible in design Minimal surface cracking

section 301 of the Trade Act of 1974, which gave the president power to unilaterally institute punitive trade restrictions on countries that engage in unfair trading with the U.S. The Chinese broke every rule. They stole everything, from tech companies’ trade secrets to pirated software, film and music, and counterfeited luxury goods and pharmaceuticals. They bought parts of companies and stole the technology. They stole intellectual property from American companies that had been required to move their technology to China to operate there.

This book is a compilation of interesting ideas that have strongly influenced my thoughts and I want to share them in a compressed form. That ideas can change your worldview and bring inspiration and the excitement of discovering something new. The emphasis is not on the technology because it is constantly changing. It is much more difficult to change the accompanying circumstances that affect the way technological solutions are realized. The chef did not invent salt, pepper and other spices. He just chooses good ingredients and uses them skilfully, so others can enjoy his art. If I’ve been successful, the book creates a new perspective for which the selection of ingredients is important, as well as the way they are smoothly and efficiently arranged together. In the first part of the book, we follow the natural flow needed to create the stimulating environment necessary for the survival of a modern company. It begins with challenges that corporations are facing, changes they are, more or less successfully, trying to make, and the culture they are trying to establish. After that, we discuss how to be creative, as well as what to look for in the innovation process. The book continues with a chapter that talks about importance of inclusion and purpose. This idea of inclusion – across ages, genders, geographies, cultures, sexual orientation, and all the other areas in which new ways of thinking can manifest – is essential for solving new problems as well as integral in finding new solutions to old problems. Purpose motivates people for reaching their full potential. This is The second and third parts of the book describes the areas that are important to support what is expressed in the first part. A flexible organization is based on IT alignment with business strategy. As a result of acceleration in the rate of innovation and technological changes, markets evolve rapidly, products’ life cycles get shorter and innovation becomes the main source of competitive advantage. Business Process Management (BPM) goes from task-based automation, to process-based automation, so automating a number of tasks in a process, and then to functional automation across multiple processes andeven moves towards automation at the business ecosystem level. Analytics brought us information and insight; AI turns that insight into superhuman knowledge and real-time action, unleashing new business models, new ways to build, dream, and experience the world, and new geniuses to advance humanity faster than ever before. Companies and industries are transforming our everyday experiences and the services we depend upon, from self-driving cars, to healthcare, to personal assistants. It is a central tenet for the disruptive changes of the 4th Industrial Revolution; a revolution that will likely challenge our ideas about what it means to be a human and just might be more transformative than any other industrial revolution we have seen yet. Another important disruptor is the blockchain - a distributed decentralized digital ledger of transactions with the promise of liberating information and making the economy more democratic. You no longer need to trust anyone but an algorithm. It brings reliability, transparency, and security to all manner of data exchanges: financial transactions, contractual and legal agreements, changes of ownership, and certifications. A quantum computer can simulate efficiently any physical process that occurs in Nature. Potential (long-term) applications include pharmaceuticals, solar power collection, efficient power transmission, catalysts for nitrogen fixation, carbon capture, etc. Perhaps we can build quantum algorithms for improving computational tasks within artificial intelligence, including sub-fields like machine learning. Perhaps a quantum deep learning network can be trained more efficiently, e.g. using a smaller training set. This is still in conceptual research domain.

Along with support by pharmaceutical giants such as Janssen Therapeutics, Johnson & Johnson, Viiv, Pfizer, Abbott Laboratories, Bristol-Myers Squibb, and Boehringer Ingelheim Pharmaceuticals, major technology corporations including Google, Microsoft, Amazon, Intel, Dell, and IBM are also funding the transgender project. In February 2017, Apple, Microsoft, Google, IBM, Yelp, PayPal, and 53 other mostly tech corporations signed onto an amicus brief pushing the US Supreme Court to prohibit schools from keeping private facilities for students designated according to sex.

Pharmaceutical companies became very interested in using siRNAs as potential new drugs. Theoretically, siRNA molecules could be used to knock down expression of any protein that was believed to be harmful in a disease. In the same year that Fire and Mello were awarded their Nobel Prize, the giant pharmaceutical company Merck paid over one billion US dollars for a siRNA company in California called Sirna Therapeutics. Other large pharmaceutical companies have also invested heavily. But in 2010 a bit of a chill breeze began to drift through the pharmaceutical industry. Roche, the giant Swiss company, announced that it was stopping its siRNA programmes, despite having spent more than $500 million on them over three years. Its neighbouring Swiss corporation, Novartis, pulled out of a collaboration with a siRNA company called Alnylam in Massachusetts. There are still plenty of other companies who have stayed in this particular game, but it would probably be fair to say there’s a bit more nervousness around this technology than in the past. One of the major problems with using this kind of approach therapeutically may sound rather mundane. Nucleic acids, such as DNA and RNA, are just difficult to turn into good drugs. Most good existing drugs – ibuprofen, Viagra, anti-histamines – have certain characteristics in common. You can swallow them, they get across your gut wall, they get distributed around your body, they don’t get destroyed too quickly by your liver, they get taken up by cells, and they work their effects on the molecules in or on the cells. Those all sound like really simple things, but they’re often the most difficult things to get right when developing a new drug. Companies will spend tens of millions of dollars – at least – getting this bit right, and it is still a surprisingly hit-and-miss process. It’s so much worse when trying to create drugs around nucleic acids. This is partly because of their size. An average siRNA molecule is over 50 times larger than a drug like ibuprofen. When creating drugs (especially ones to be taken orally rather than injected) the general rule is, the smaller the better. The larger a drug is, the greater the problems with getting high enough doses into patients, and keeping them in the body for long enough. This may be why a company like Roche has decided it can spend its money more effectively elsewhere. This doesn’t mean that siRNA won’t ever work in the treatment of illnesses, it’s just quite high risk as a business venture.

In universities and pharmaceutical labs around the world, computer scientists and computational biologists are designing algorithms to sift through billions of gene sequences, looking for links between certain genetic markers and diseases. The goal is to help us sidestep the diseases we're most likely to contract and to provide each one of us with a cabinet of personalized medicines. Each one should include just the right dosage and the ideal mix of molecules for our bodies. Between these two branches of research, genetic and behavioral, we're being parsed, inside and out. Even the language of the two fields is similar. In a nod to geneticists, Dishman and his team are working to catalog what they call our "behavioral markers." The math is also about the same. Whether they're scrutinizing our strands of DNA or our nightly trips to the bathroom, statisticians are searching for norms, correlations, and anomalies. Dishman prefers his behavioral approach, in part because the market's less crowded. "There are a zillion people looking at biology," he says, "and too few looking at behavior." His gadgets also have an edge because they can provide basic alerts from day one. The technology indicating whether a person gets out of bed, for example, isn't much more complicated than the sensor that automatically opens a supermarket door. But that nugget of information is valuable. Once we start installing these sensors, and the electronics companies get their foot in the door, the experts can start refining the analysis from simple alerts to sophisticated predictions-perhaps preparing us for the onset of Parkinson's disease or Alzheimer's.

In universities and pharmaceutical labs around the world, computer scientists and computational biologists are designing algorithms to sift through billions of gene sequences, looking for links between certain genetic markers and diseases. The goal is to help us sidestep the diseases we're most likely to contract and to provide each one of us with a cabinet of personalized medicines. Each one should include just the right dosage and the ideal mix of molecules for our bodies. Between these two branches of research, genetic and behavioral, we're being parsed, inside and out. Even the language of the two fields is similar. In a nod to geneticists, Dishman and his team are working to catalog what they call our "behavioral markers." The math is also about the same. Whether they're scrutinizing our strands of DNA or our nightly trips to the bathroom, statisticians are searching for norms, correlations, and anomalies. Dishman prefers his behavioral approach, in part because the market's less crowded. "There are a zillion people looking at biology," he says, "and too few looking at behavior." His gadgets also have an edge because they can provide basic alerts from day one. The technology indicating whether a person gets out of bed, for example, isn't much more complicated than the sensor that automatically opens a supermarket door. But that nugget of information is valuable. Once we start installing these sensors, and the electronics companies get their foot in the door, the experts can start refining the analysis from simple alerts to sophisticated predictions-perhaps preparing us for the onset of Parkinson's disease or Alzheimer's.

the group existed, these six had been accumulating shares in key industries such as communications, transport, banking, pharmaceutical, medical, technology and other key industries worldwide. They were shrewd enough to hide what they were doing – very seldom would they buy controlling shares, and never in their personal names. Instead, the acquisitions were always through companies that owned companies that owned yet more companies - hiding themselves five, six or more levels away from the front, the public eye and any security screens.

XM29 OICW ni bunduki iliyowasaidia Vijana wa Tume kubomoa jengo la utawala la Kolonia Santita katika Kiwanda cha Dongyang Pharmaceuticals jijini Mexico City, iliyowasaidia kukamata baadhi ya wakurugenzi wa Kolonia Santita kabla hawajatoroshwa na walinzi wao makomandoo. Bunduki hii inayotumia teknolojia ya OICW ('Objective Individual Combat Weapon') iliyotengenezwa na Kiwanda cha Heckler & Koch cha Ujerumani, ina uwezo wa kufyatua makombora ya HEAB ('High Explosive Air Bursting') yenye ukubwa wa milimeta 20; ambayo hulipuka hewani kabla ya kugonga shabaha, kwa lengo la kusambaza vyuma vya moto katika eneo lote walipojificha maadui. Bunduki hizi hazitumiki tena. Zilitumika mara ya mwisho mwaka 2004.

Pharmaceutical and health companies, communications through all media (TV, newspapers, internet, telephones), energy where Tenth Cycle technology hadn’t yet arrived, transport including airlines, shipping, rail and road transport, along with military contractors, big agro and big pharma, and technology companies; all were controlled by a handful of companies whose names showed up over and over. They were always in a minority shareholder position individually, but as a group the controlling interest was overwhelming.

We are a large global Life Sciences consulting company with world-class experience in technology and management consulting, and software product development for large pharmaceutical companies.

Well, it depends which planned economies you mean. There are lots of planned economies―the United States is a planned economy, for example. I mean, we talk about ourselves as a "free market," but that's baloney. The only parts of the U.S. economy that are internationally competitive are the planned parts, the state-subsidized parts―like capital-intensive agriculture (which has a state-guaranteed market as a cushion in case there are excesses); or high-technology industry (which is dependent on the Pentagon system); or pharmaceuticals (which is massively subsidized by publicly-funded research). Those are the parts of the U.S. economy that are functioning well. And if you go to the East Asian countries that are supposed to be the big economic successes―you know, what everybody talks about as a triumph of free-market democracy—they don't even have the most remote relation to free-market democracy: formally speaking they're fascist, they're state-organized economies run in cooperation with big conglomerates. That's precisely fascism, it's not the free market. Now, that kind of planned economy "works," in a way―it produces at least. Other kinds of command economies don't work, or work differently: for example, the Eastern European planned economies in the Soviet era were highly centralized, over-bureaucratized, and they worked very inefficiently, although they did provide a kind of minimal safety-net for people. But all of these systems have been very anti-democratic―like, in the Soviet Union, there were virtually no peasants or workers involved in any decision-making process.

At the third special session, a host of developing countries demanded that the United States, Russia, Japan, China, and the European Union release their technology and provide all advanced technology, including aerospace technology, free of charge to the international community so that all nations of humanity would have an equal opportunity to face the Trisolar Crisis. The supporters of the socialized technology movement brought up a precedent: At the beginning of the century, several major European pharmaceutical companies exacted high license fees from African countries for the manufacture of state-of-the-art AIDS treatments, prompting high-profile litigation. Under pressure from public opinion and the rapid spread of the disease in Africa, the companies renounced their patent rights prior to trial. The ultimate crisis that Earth is now facing means that open technology is the unavoidable responsibility that advanced countries have to all humanity. The socialized technology movement found a unanimous response from developing countries and even won the support of some members of the EU, but all related initiatives were rejected at meetings of the UN-PDC.

Now it seems that the nasty people are those who question the direction of our society, our loss of liberty, our submission to technology and domination of the security, industrial, military and pharmaceutical society (SIMP). We are living in the SIMP society and we are the Simpsons.

The Love of Money It is not money in itself but the “love of money” that is the root of all evil. When the threat of Climate Change became a national crisis, the families of noted politicians began investing their money in “new green technology,” including solar panels, wind turbines, and electric cars, as informed investors invest where future money is to be made. When COVID hit, there were already certain pharmaceuticals that were used to treat the virus, including one I took that helped me within 48 hours. However, these pills have been available for many years to help prevent malaria but were ignored or not permitted to be sold, as the companies creating the vaccines and various doctors put the word out that these pills were not effective, and only the vaccine would work. According to whistleblower-doctors, the underlying reason for rejecting a cheaper pill is because vaccines would create more money.

PCD & Franchise Company, International Standard Quality Products in Ahmedabad Gujarat India. Desta Life Sciences is the top PCD Pharma Franchise company in India. We are procured from faithful vendors to ensure its International Standard Quality Products. We're at Desta Science for Health Life providing the best PCD Franchise for business. This is the best Business Opportunity in India. We have 200+ Products, 4 Divisions and 13 Innovative Products. Desta Lifesciences, Started in 2011. The company's philosophy has been rooted in Quality and care and it is this ideology that has kept us alive through ups and downs. The company's greatest asset has always been its employees and it is in them we place our trust to shoulder the company's corporate responsibility and to uphold the company's ideals and values. A healthy blend of World-Class Quality, Disease prevalence-dependent, wide variety of products, stress on preventive Lifestyle products, a positive upbeat mood of one & all in the company and a feeling of oneness, is the recipe that Desta Lifesciences presents humbly to humanity. The "For the people, By the People" dictum is followed by the management in the company, thus making it surge forward with the force of the common goal to accomplish our Mission. We aim to serve mankind globally through our affordable and international standard quality products, encompassing the environmental synergy in the process. As we enter into the technological age of pharmaceuticals, we promise to adapt to more advanced technologies while simultaneously focusing on delivery of care. The future holds great promise as we gradually hope to venture into Exports and R&D to establish ourselves in the global market.

India's Leading Dermatology Third Party Pharma Manufacturing Company Today, the world's pharmaceutical industry is growing by leaps and bounds; and India is showing the most promising signs in this industry. We undertake our quest of improving the quality of human life with enthusiasm and vigor. Our vision for the future is powered by our business drivers. It finds purpose and direction with our strategic intent. Understanding how diseases develop and the preventive measures that can be adopted to avoid them are important steps in staying healthy. Dermatology is the branch of medicine dealing with the skin, nails, hair, and its diseases. It is a specialty with both medical and surgical aspects. A dermatologist treats diseases, in the widest sense, and some cosmetic problems of the skin, scalp, hair, and nails. Our latest range of treatment and therapy solutions gives healthcare professionals the opportunity to offer individualized care to their patients. And an array of delivery options including systemic, topical, and BioPhotonic technologies - allows doctors and nurses to tailor their treatments to the lifestyle of each individual patient We also accept Third Party Manufacturing order and have major Client base in Nigeria, Kenya, Nepal, Sri Lanka, Myanmar, Sudan, Philippines, Vietnam, Cambodia. All mine Face Lotion for Moisturizing & Dry Skin Lotion, Face Lotion for Moisturizing, Allmine Lotion Moisturizes, Allmine Lotion, Body Lotion.

Pharmaceutical Product Exporters in Ahmedabad India’s Leading Exporters of Quality Pharmaceutical Formulations in India. We offer Pharmaceutical Drug Formulation and Pharmaceutical Marketers. Research Pvt. Ltd. is top manufacturing the anti-infective Tablets. We have a wide range of pharmaceutical product exporters in Ahmedabad India. ERPL is one of the fastest growing pharmaceutical manufacturing company in India. Spread over 1,47,500 sq. ft. acres, this modernized manufacturing plant with ultra-modern facility is set up in North Indian State of Uttarakhand. The facilities are approved by cGMP, WHO-GMP, GLP, ISO 9001:2000 and other global regulatory bodies. ERPL has carved out a distinct place of its own in manufacturing of best quality pharmaceutical products. Our success is the mirror of the hard work and team spirit put up the excellence of the professionalism by our dedicated Directors to excel and concurred new horizons with the motive of “Commit to Quality and Customer Satisfaction” Manufacturing Facility Installed with latest technology, automated manufacturing and packing operation and best practices, ensuring the highest quality of healthcare. • Commitment and zero compromise on quality • Follow up WHO-GMP, CGMP and GLP • Instrument Lab • Primary Area • Analytical Lab • Production process • Quality Management system • Process and products design, Evolution & Validation of process.

We are chemical apes: having discovered the capacity to extract, purify, and react molecules to produce new and wondrous molecules, we have begun to spin a new chemical universe around ourselves. Our bodies our cells, our genes are thus being immersed and reimmersed in a changing flux of molecules -pesticides, pharmaceutical drugs, plastics, cosmetics, estrogens, food products, hormones, even novel forms of physical impulses, such as radiation and magnetism. Some of these, inevitably, will be carcinogenic. We cannot wish this world away; our task, the, is to sift through it vigilantly to discriminate bona fide carcinogens from innocent and useful bystanders.

P2 - We are well on the way in a number of areas. Both billionaires and big Pharma are getting increasingly interested and money is starting to pour into research because it is clear we can see the light at the end of the tunnel which to investors equates to return on investment. Numerous factors will drive things forward and interest and awareness is increasing rapidly among both scientists, researchers and the general population as well as wealthy philanthropists. The greatest driving force of all is that the baby boomers are aging and this will place increasing demands on healthcare systems. Keep in mind that the average person costs more in medical expenditure in the last year of their life than all the other years put together. Also, the number of workers is declining in most developed countries which means that we need to keep the existing population working and productive as long as possible. Below are a list which are basically all technologies potentially leading to radical life extension with number 5 highlighted which I assume might well be possible in the second half of the century: 1. Biotechnology - e.g stem cell therapies, enhanced autophagy, pharmaceuticals, immunotherapies, etc 2. Nanotechnology - Methods of repairing the body at a cellular and molecular level such as nanobots. 3. Robotics - This could lead to the replacement of increasing numbers of body parts and tends to go hand in hand with AI and whole brain emulation. It can be argued that this is not life extension and that it is a path toward becoming a Cyborg but I don’t share that view because even today we don’t view a quadriplegic as less human if he has four bionic limbs and this will hold true as our technology progresses. 4. Gene Therapies - These could be classified under the first category but I prefer to look at it separately as it could impact the function of the body in very dramatic ways which would suppress genes that negatively impact us and enhance genes which increase our tendency toward longer and healthier lives. 5. Whole brain emulation and mindscaping - This is in effect mind transfer to a non biological host although it could equally apply to uploading the brain to a new biological brain created via tissue engineering this has the drawback that if the original brain continues to exist the second brain would have a separate existence in other words whilst you are identical at the time of upload increasing divergence over time will be inevitable but it means the consciousness could never die provided it is appropriately backed up. So what is the chance of success with any of these? My answer is that in order for us to fail to achieve radical life extension by the middle of the century requires that all of the above technologies must also fail to progress which simply won't happen and considering the current rate of development which is accelerating exponentially and then factoring in that only one or two of the above are needed to achieve life extension (although the end results would differ greatly) frankly I can’t see how we can fail to make enough progress within 10-20 years to add at least 20 to 30 years to current life expectancy from which point progress will rapidly accelerate due to increased funding turning aging at the very least into a manageable albeit a chronic incurable condition until the turn of the 22nd century. We must also factor in that there is also a possibility that we could find a faster route if a few more technologies like CRISPR were to be developed. Were that to happen things could move forward very rapidly. In the short term I'm confident that we will achieve significant positive results within a year or two in research on mice and that the knowledge acquired will then be transferred to humans within around a decade. According to ADG, a dystopian version of the post-aging world like in the film 'In Time' not plausible in the real world: "If you CAREFULLY watch just the first

Pharmaceutical Syrup Manufacturers Saphnix Life Sciences is an emerging and fastest-growing Pharmaceutical Syrup Manufacturers. Our company is well based in Chandigarh and popular for its best high-quality wide range of Syrup range. We the best Syrup Range Manufacturer in India are capable of carrying out large-scale manufacturing and supplying various varieties of syrups/suspension ranges to many pharma companies all around India. WE FOLLOW THE LATEST AND MOST ADVANCED SYRUP MANUFACTURING TOOLS Our company has built its modern, fully developed infrastructure. Maximum possible use of technology and sources lead us to manufacture medicines cost-effectively. To obtain pure, safe, and non-contaminated medicines, we use sterilized machinery to manufacture and package the medicines. The company is using all the quality methods for syrup/suspension manufacturing. Different manufacturing tools for syrup include- 1. Control Panel 2. Product Piping 3. Storage Vessel 4. Working Platform 5. Sugar Syrup Vessel 6. Manufacturing Vessel Salient Features In addition to the above, you can also choose us for these reasons: • -On-time delivery • -Year around stock availability • -24*7 customer support • -Quality medicinal drugs • -Appealing packaging Saphnix Lifesciences: Proudly the best Pharmaceutical Syrup manufacturer in India.

Our pursuit of instant gratifications and instant progress has been leading us down the path of mental deterioration and we seem to be completely unaware of it. And if this continues, then soon serenity will become the most expensive commodity in the market - which will be sold to everyone by the pharmaceutical industry in the form of pills and treatments.

During an interview with Diversity Inc.’s director of research and product development, she walked me through a typical presentation used to pitch the value of the company’s software to prospective clients. I learned that their products are especially valuable to those industries not allowed to collect ethno-racial data directly from individuals because of civil rights legislation that attempts to curb how these data are used to discriminate. But now those who work in finance, housing, and healthcare can use predictive software programs to ascertain information that they cannot request directly. The US Health Insurance Portability and Accountability Act (HIPAA) privacy rule, for example, strictly monitors the collection, storage, and communication of individuals’ “protected health information,” among other features of the law. This means that pharmaceutical companies, which market to different groups, need indirect methods to create customer profiles, because they cannot collect racial-ethnic data directly. This is where Diversity Inc. comes in. Its software programs target customers not only on the basis of race and ethnicity, but also on the basis of socioeconomic status, gender, and a growing list of other attributes. However, the company does not refer to “race” anywhere in their product descriptions. Everything is based on individuals’ names, we are told. “A person’s name is data,” according to the director of research and product development. She explains that her clients typically supply Diversity Inc. with a database of client names and her team builds knowledge around it. The process, she says, has a 96 percent accuracy rate, because so many last names are not shared across racial–ethnic groups – a phenomenon sociologists call “cultural segregation.”18

The dysfunctional state of the American political system is the best reason to be pessimistic about our country’s future. Our scientific and technological prowess is the best reason to be optimistic. We are an inventive people. The United States produces ridiculous numbers of patents,114 has many of the world’s best universities and research institutions, and our companies lead the market in fields ranging from pharmaceuticals to information technology. If I had a choice between a tournament of ideas and a political cage match, I know which fight I’d rather be engaging in—especially if I thought I had the right forecast.

ABOUT THE AUTHOR Tim Tigner began his career in Soviet Counterintelligence with the US Army Special Forces, the Green Berets. That was back in the Cold War days when, “We learned Russian so you didn't have to,” something he did at the Presidio of Monterey alongside Recon Marines and Navy SEALs. With the fall of the Berlin Wall, Tim switched from espionage to arbitrage. Armed with a Wharton MBA rather than a Colt M16, he moved to Moscow in the midst of Perestroika. There, he led prominent multinational medical companies, worked with cosmonauts on the MIR Space Station (from Earth, alas), chaired the Association of International Pharmaceutical Manufacturers, and helped write Russia’s first law on healthcare. Moving to Brussels during the formation of the EU, Tim ran Europe, Middle East and Africa for a Johnson & Johnson company and traveled like a character in a Robert Ludlum novel. He eventually landed in Silicon Valley, where he launched new medical technologies as a startup CEO. In his free time, Tim has climbed the peaks of Mount Olympus, hang glided from the cliffs of Rio de Janeiro, and ballooned over Belgium. He earned scuba certification in Turkey, learned to ski in Slovenia, and ran the Serengeti with a Maasai warrior. He acted on stage in Portugal, taught negotiations in Germany, and chaired a healthcare conference in Holland. Tim studied psychology in France, radiology in England, and philosophy in Greece. He has enjoyed ballet at the Bolshoi, the opera on Lake Como, and the symphony in Vienna. He’s been a marathoner, paratrooper, triathlete, and yogi.

ABOUT MATIYAS We are an enthusiastic and energetic establishment dedicated to bringing automation and transforming business processes digitally. We understand the value of technological advancements for increasing productivity and enhancing quality, and our in-house teams of dedicated professionals offer various services to achieve this objective effectively. Matiyas digital solutions help to streamline manufacturing business functions, increase profitability, automating efforts and increase the quality of production. Our Customized manufacturing digital solutions can assist you to address all the hurdles that occur during the manufacturing process. You can have complete control over the manufacturing process by handling inventory management and supply chain management effectively. At Matiyas, we are committed to bringing digital transformation in manufacturing through advanced solutions and excellent services Matiyas is providing industry 4.0 digital solutions to: • Oil & Gas • Cement Manufacturing • Electronics Manufacturing • Industrial Machinery and Equipment • Steel Manufacturing • Plastic Manufacturing • Packaging Manufacturing • Power Plants • Pharmaceutical • Fast Moving Consumer Goods (FMCG) • Medical Devices Industry • EPC Our digital solutions empower the manufacturers to closely supervise each and every stage of the manufacturing process and gives the absolute control over it, as a result you observe an ample reduction in wastage and material exchange possibilities which not only improves production quality but quantity too. We understand the major problems manufacturing businesses come across and we tailor best manufacturing digital solutions accordingly. HOW OUR MANUFACTURING DIGITAL SOLUTIONS CAN BENEFIT YOUR ORGANIZATION? Increased ROI Reduced Operational Costs & Optimize Operations Enhanced Resource Utilization & Reduced Overheads Deeper insights about your supply chains & production Improved Agility, Higher productivity Easier Collaboration Accountability and transparency And Many More .... Matiyas Digital Solutions: Inventory Management, Procurement Management, Selling Management, Production Management, Retail POS Management, Manufacturing Management, Project Management, Customer Relationship Management, Accounting & Finance Management, Human Capital Management, Assets Management, Quality Management, Ecommerce, Website, Hospital Management Information System HMIS, Education Management and many more… Matiyas Offices: India, Oman, Kuwait, Canada, UAE, Armenia, Africa, Egypt Interested to Automate and Collaborate Effectively Through Our Custom Digital Solutions?

In business studies, value is understood as being created inside the company by bringing together managerial expertise, strategic thinking and a dynamic (changing with circumstances) division of labour between workers.3 All this ignores the massive role of government in creating value, and taking risk in the process. In The Entrepreneurial State I argued that Silicon Valley itself is an outcome of such high-risk investments by the state, willing to take risks in the early stages of development of high-risk technologies which the private sector usually shies away from.4 This is the case with the investments that led to the internet, where a critical role was played by DARPA, the Defence Advanced Research Projects Agency inside the US Department of Defense – and also by CERN in Europe with its invention of the World Wide Web. Indeed, not only the internet but nearly every other technology that makes our smart products smart was funded by public actors, such as GPS (funded by the US Navy), Siri (also funded by DARPA) and touch-screen display (funded initially by the CIA). It is also true of the high-risk, early-stage investments made in the pharmaceutical industry by public actors like the National Institutes of Health (NIH) – without which most blockbuster drugs would not have been developed. And the renewable energy industry has been greatly aided by investments made by public banks like the European Investment Bank or the KfW in Germany, with private finance often too risk-averse and focused on short-term returns.

Today’s technology is heavily contaminating the environment with many behavior-disturbing, endocrine-disrupting chemicals (EDCs) that include dioxin, phthalates, agricultural pesticides, polychlorinated biphenyls (PCBs), industrial solvents, pharmaceuticals, and heavy metals. Exposure to these EDCs that have estrogenic, antiestrogenic, and antiandrogenic properties has been shown to perturb the same stress pathways that provoke a disease response. (Vaiserman 2014)

Top Skills Australia Wants for the Global Talent Visa The Global Talent Visa (subclass 858) is one of Australia’s most prestigious visa programs, designed to attract highly skilled professionals who can contribute to the country’s economy and innovation landscape. Australia is looking for exceptional talent across various sectors to support its economic growth, technological advancements, and cultural development. If you’re considering applying for the Global Talent Visa, understanding the skills in demand will help you position yourself as a strong candidate. In this blog, we’ll outline the top skills and sectors Australia prioritizes for the Global Talent Visa, and why these skills are so valuable to the country’s future development. 1. Technology and Digital Innovation Australia is rapidly embracing digital transformation across industries, and the technology sector is one of the highest priority areas for the Global Talent Visa. Skilled professionals in cutting-edge technologies are highly sought after to fuel innovation and help Australia stay competitive in the global economy. Key Tech Skills in Demand: Cybersecurity: With increasing cyber threats globally, Australia needs experts who can safeguard its digital infrastructure. Cybersecurity professionals with expertise in network security, data protection, and ethical hacking are in high demand. Software Development & Engineering: Australia’s digital economy thrives on skilled software engineers and developers. Professionals who are proficient in programming languages like Python, Java, and C++, or who specialize in areas such as cloud computing, DevOps, and systems architecture, are highly valued. Artificial Intelligence (AI) & Machine Learning (ML): AI and ML are transforming industries ranging from healthcare to finance. Experts in AI algorithms, natural language processing, deep learning, and neural networks are in demand to help drive this technology forward. Blockchain & Cryptocurrency: Blockchain technology is revolutionizing sectors like finance, supply chains, and data security. Professionals with expertise in blockchain development, smart contracts, and cryptocurrency applications can play a key role in advancing Australia's digital economy. 2. Healthcare and Biotechnology Australia has a robust and expanding healthcare system, and the country is heavily investing in medical research and biotechnology to meet the needs of its aging population and to drive innovation in health outcomes. Professionals with advanced skills in biotechnology, medtech, and pharmaceuticals are crucial to this push. Key Healthcare & Bio Skills in Demand: Medical Research & Clinical Trials: Australia is home to a growing number of research institutions that focus on new treatments, vaccines, and therapies. Researchers and professionals with experience in clinical trials, molecular biology, and drug development can contribute to the ongoing advancement of Australia’s healthcare system. Biotechnology & Genomics: Experts in biotechnology, particularly those working in genomics, gene editing (e.g., CRISPR), and personalized medicine, are highly sought after. Australia is investing heavily in biotech innovation, especially for treatments related to cancer, cardiovascular diseases, and genetic disorders. MedTech Innovation: Professionals developing the next generation of medical technologies—ranging from diagnostic tools and medical imaging to wearable health devices and robotic surgery systems—are in high demand. If you have experience in health tech commercialization, you could find significant opportunities in Australia.

Under a clean-swept summer sky stretching over both industrial zones and uniform housing, I take the suburban train southeast, to the edge of Berlin. In order to find the remnants of the Temmler factory I have to get out at Adlershof, which nowadays calls itself “Germany’s most modern technology park.” Avoiding the campus, I strike off across an urban no-man’s-land, skirting dilapidated factory buildings and passing through a wilderness of crumbling brick and rusty steel. The Temmler factory moved here in 1933. It was only one year later that Albert Mendel (the Jewish co-owner of the Tempelhof Chemical Factory) was expropriated by the racist laws of the regime and Temmler took over his share, quickly expanding the business. These were good times for the German chemical industry (or at least for its Aryan members), and pharmaceutical development boomed. Research was tirelessly conducted on new, pioneering substances that would ease the pain of modern humanity or sedate its troubles. Many of the resulting pharmacological innovations shape the way we consume medicine today.

To understand the historical relevance of methamphetamine and other substances to the Nazi state, we must go back before the beginning of the Third Reich. The development of modern societies is bound as tightly with the creation and distribution of drugs as the economy is with advances in technology. In 1805 Goethe wrote Faust in classicist Weimar, and by poetic means perfected one of his theses, that the genesis of man is itself drug-induced: I change my brain, therefore I am. At the same time, in the rather less glamorous town of Paderborn in Westphalia, the pharmaceutical assistant Friedrich Wilhelm Sertürner performed experiments with opium poppies, whose thickened sap anesthetized pain more effectively than anything else. Goethe wanted to explore through artistic and dramatic channels what it is that holds the core of the world together—